** Shares of Boston-based drug developer PepGen PEPG.O fall 9% to $2.56 premarket

** Company says it will temporarily pause mid-stage study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD)

** Says the study is paused until company can review results from patient group dosed with 10 mg/kg, which is expected during Q3

** DMD is a genetic disorder causing progressive muscle weakness and degeneration

** Company says no new safety issues related to PGN-EDO51 have been observed since the company's last safety update in January

** PEPG has fallen 83% in the last 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))